---
title: "SINOPHARM: Operating profit of 7.45 billion yuan in the first half of the year"
description: "SINOPHARM announced on the Hong Kong Stock Exchange that its revenue for the first half of the year was 286 billion RMB, operating profit was 7.45 billion RMB, net profit was 3.47 billion RMB, and gro"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254334453.md"
published_at: "2025-08-24T22:10:20.000Z"
---

# SINOPHARM: Operating profit of 7.45 billion yuan in the first half of the year

> SINOPHARM announced on the Hong Kong Stock Exchange that its revenue for the first half of the year was 286 billion RMB, operating profit was 7.45 billion RMB, net profit was 3.47 billion RMB, and gross profit margin was 7.11%

SINOPHARM announced on the Hong Kong Stock Exchange that its revenue for the first half of the year was 286 billion RMB, operating profit was 7.45 billion RMB, net profit was 3.47 billion RMB, and gross profit margin was 7.11%

### Related Stocks

- [01099.HK - SINOPHARM](https://longbridge.com/en/quote/01099.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 高瓴继续重仓中概股，HHLR 四季度增持阿里巴巴、拼多多，减持网易、百度 | 高瓴 HHLR Advisors Ltd.在四季度增持了阿里巴巴、拼多多、iShares 比特币和台积电，同时减持了网易、Bright Schol、富途控股、百度、满帮和 Webull 等。该公司重仓拼多多、阿里巴巴和富途控股。市场有风险， | [Link](https://longbridge.com/en/news/276176972.md) |
| Select 医药控股｜10-K：2025 财年营收 54.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276384073.md) |
| 宏盟集团｜10-K：2025 财年营收 173 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276492573.md) |
| Pulse Biosciences｜10-K：2025 财年营收 35 万美元 |  | [Link](https://longbridge.com/en/news/276378133.md) |
| IRhythm｜8-K：2025 财年 Q4 营收 2.09 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276378830.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
